返回
Breast cancer
DOI:10.1016/S0140-6736(05)66546-4.png)
摘要
En 中文
Breast cancer remains a public-health issue on a global scale. We report new information about the disease from the past 5 years. Early age at first birth, increasing parity, and tamoxifen use are related to long-term lifetime reduction in breast-cancer risk. Ductal carcinomas in situ has been suggested to be renamed ductal intraepithelial neoplasia to emphasise its non-life-threatening nature. An alternative approach, the progenitor/stem cell theory, predicts that only some tumour cells cause cancer progression and that these should be targeted by treatment. Mammography and ultrasonography are still the most effective for women with non-dense and dense breast tissues, respectively. Additionally, MRI, lymphatic mapping, the nipple-sparing mastectomy, partial breast irradiation, neoadjuvant systemic therapy, and adjuvant treatments are promising for subgroups of breast-cancer patients. Although tamoxifen can be offered for endocrine-responsive disease, aromatase inhibitors are increasingly used. Assessment of potential molecular targets is now important in primary diagnosis. Tyrosine-kinase inhibitors and other drugs with anti-angiogenesis properties are currently undergoing preclinical investigations.
Keyword:
CARCINOMA IN-SITU
ADJUVANT ENDOCRINE THERAPY
POSITIVE PREMENOPAUSAL WOMEN
ESTROGEN-RECEPTOR STATUS
SENTINEL LYMPH-NODES
POOLED ANALYSIS
AXILLARY DISSECTION
HIGH-RISK
INTRAOPERATIVE RADIOTHERAPY
POSTOPERATIVE RADIOTHERAPY
AI总结
对已上传原文的论文进行重点信息的提取,主要内容包括:简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
88.5
论文数:
5.4W
被引数:
34.8W
机构
暂无机构信息
引用论文
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer - Results of the ATAC (arimidex, tamoxifen alone or in comhination) trial efficacy and safety update analyses阿那曲唑单独或与他莫昔芬联合与他莫昔芬单独用于绝经后早期乳腺癌妇女的辅助治疗-ATAC (arimidex,他莫昔芬单独或联合) 试验的结果有效性和安全性更新分析
CANCER
IF5.1
Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50 302 women with breast cancer and 96 973 women without the disease
LANCET
IF88.5

